Caricamento...
Emerging treatments in management of prostate cancer: biomarker validation and endpoints for immunotherapy clinical trial design
The rapidly emerging field of immunotherapy and the development of novel immunologic agents that have been approved in melanoma and successfully studied in lung cancer, kidney cancer, and prostate cancer have mandated that there be uniformity in clinical trial analysis beyond conventional survival e...
Salvato in:
| Pubblicato in: | Immunotargets Ther |
|---|---|
| Autore principale: | |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Dove Medical Press
2013
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4918229/ https://ncbi.nlm.nih.gov/pubmed/27471695 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/ITT.S30821 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|